Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DEGS1 | O15121 | 1/20 | 0.37 |
| ▸ | ABL1 | P00519 | 4/20 | 0.37 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.33 |
| ▸ | ACACB | O00763 | 4/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2343120 | 1.00 | DEGS1 (0.37) | DEGS1ABL1MTNR1AMTNR1BACACB | |
| SCHEMBL2343085 | 0.87 | DEGS1 (0.37) | DEGS1MTNR1AMTNR1BACACBNPSR1 | |
| SCHEMBL3320370 | 0.84 | ABL1 (0.39) | DEGS1ABL1MTNR1AMTNR1BACACB | |
| SCHEMBL2337580 | 0.84 | ABL1 (0.39) | DEGS1ABL1MTNR1AMTNR1BACACB | |
| SCHEMBL2336740 | 0.83 | DEGS1 (0.50) | DEGS1ABL1ACACBNPSR1LMNA | |
| SCHEMBL2336745 | 0.83 | DEGS1 (0.50) | DEGS1ABL1ACACBNPSR1LMNA | |
| SCHEMBL2347988 | 0.83 | DEGS1 (0.50) | DEGS1ABL1ACACBNPSR1LMNA | |
| SCHEMBL3320103 | 0.82 | DEGS1 (0.34) | DEGS1MTNR1AMTNR1BACACB | |
| SCHEMBL2342388 | 0.82 | DEGS1 (0.34) | DEGS1MTNR1AMTNR1BACACB | |
| SCHEMBL21380386 | 0.76 | DEGS1 (0.35) | DEGS1ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8642590-B2 | Alkylcyclohexylethers of dihydrotetraazabenzoazulenes | HOFFMANN-LA ROCHE INC. (US) | 2014-02-04 | — | — | US | disclosed |
| EP-2358714-B1 | ALKYLCYCLOHEXYLETHERS OF DIHYDROTETRAAZABENZOAZULENES | HOFFMANN LA ROCHE (CH) | 2012-08-01 | — | — | EP | disclosed |
| US-20100125066-A1 | ALKYLCYCLOHEXYLETHERS OF DIHYDROTETRAAZABENZOAZULENES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100125066-A1 | ALKYLCYCLOHEXYLETHERS OF DIHYDROTETRAAZABENZOAZULENES | AVPR1A, AVPR1B, OXTR | DEGS1 784/4885ABL1 1999/4885MTNR1A 421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.